Physician profile

Angela Wei

Cleveland, OH

NPI 1467200345

$640.21

in general payments reported to CMS, 2019-2025

7 companies · $640 in 2025

The $640 reported for 2025 was more than what 83% of providers received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$640.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Incyte Corporation $241.64 2025 Opzelura, Opzelura
Novartis Pharmaceuticals Corporation $125.50 2025
Lnhc, INC $102.40 2025 Zelsuvmi
Arcutis Biotherapeutics, INC. $98.31 2025 Zoryve
Organon LLC $31.05 2025 Vtama
Biofrontera INC. $21.00 2025 Ameluz
Amgen INC. $20.31 2025 Otezla

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Angela Wei

$640.21

in general payments reported 2019-2025

Years
2025
Top company
Incyte Corporation
Context
The $640 reported for 2025 was more than what 83% of providers received nationally.

https://glasscript.com/doctor/11949678/angela-wei

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.